| Hazard Information | Back Directory | [Uses]
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity[1]. | [in vivo]
ADCT-601 (3 mg/kg, 6 mg/kg; i.v.; single dose) is safety and tolerability in non-tumor-bearing male Sprague-Dawley rats[1].
ADCT-601 (1 mg/kg; i.v.; once daily for 60 days) shows potent and sustained antitumor activity for mouse in both MDA-MB-231 TNBC xenograft model and SN12C renal cancer xenograft model[1].
ADCT-601 (0.075, 0.15, or 0.3 mg/kg; i.v.; once daily for 45 days) also dose-dependently in a pancreatic cancer PDX model (PAXF1657) with heterogeneous AXL expression[1].
| Animal Model: | Mouse model with SN12C renal cancer xenograft or MDA-MB-231 TNBC xenograft[1] | | Dosage: | 0.3, 0.6, and 1 mg/kg | | Administration: | Intravenous injection; once daily for 60 days | | Result: | Significantly inhibited the growth of tumor volume in vivo in mouse. |
| [IC 50]
Axl | [References]
[1] Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593. DOI:10.1158/1535-7163.MCT-21-0715 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|